A scientist works at a drug development facility in Shanghai. Photo: Reuters

Don’t get burnt: Hong Kong biotech stock Genscript is hot stuff but also high risk

Without profit model details of a new R&D work for cancer immunotherapy contract and commercialisation success records, analysts warned investors to ‘handle with care’

Topic |   Pharmaceuticals

TOP PICKS

A scientist works at a drug development facility in Shanghai. Photo: Reuters
READ FULL ARTICLE